SVA Share Price

Open 5.05 Change Price %
High 5.39 1 Day 0.21 4.16
Low 5.04 1 Week 0.62 13.36
Close 5.26 1 Month -0.35 -6.24
Volume 132506 1 Year -0.83 -13.63
52 Week High 6.45
52 Week Low 4.60
SVA Important Levels
Resistance 2 5.58
Resistance 1 5.45
Pivot 5.23
Support 1 5.07
Support 2 4.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Sinovac Biotech, Ltd. (NASDAQ: SVA)

SVA Technical Analysis 3
As on 26th May 2017 SVA Share Price closed @ 5.26 and we RECOMMEND Sell for LONG-TERM with Stoploss of 5.81 & Sell for SHORT-TERM with Stoploss of 5.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
SVA Target for May
1st Target up-side 5.71
2nd Target up-side 5.81
3rd Target up-side 5.91
1st Target down-side 5.43
2nd Target down-side 5.33
3rd Target down-side 5.23
SVA Other Details
Segment EQ
Market Capital 148553632.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.sinovac.com
SVA Address
SVA
No. 39 Shangdi Xi Road
Haidian District
Beijing, 100085
China
Phone: 86 10 8289 0088
Fax: 86 10 6296 6910
SVA Latest News
Interactive Technical Analysis Chart Sinovac Biotech, Ltd. ( SVA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sinovac Biotech, Ltd.
SVA Business Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company�s product pipeline also includes human vaccines against rotavirus, and human rabies that are in pre-clinical development. The Company specializes in the sales, marketing, manufacturing, and development of vaccines for infectious disease with unmet medical need. The Company�s pipeline consists of vaccine candidates in the clinical and pre-clinical development phases in China, including the EV71 vaccine and human vaccines for pneumococcal, rotavirus, rabies, varicella and rubella.